AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 302 min read$NTRA

Rabinowitz Matthew sold $448K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 1,718 shares of Natera, Inc. (NTRA) at $260.49 ($0.45M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not introduce new company performance information.

02

Market read

Insider selling can influence short-term sentiment, but the 10b5-1 structure suggests limited informational content.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance, trial, or contract updates, the fundamental read-through is weak.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29, covering a sale dated 2026-07-27.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc. involving the executive chairman.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 1,718 shares in an open-market transaction on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 insider sale and explicitly notes a pre-arranged 10b5-1 plan, reducing signaling risk.

Market effects

Sector

Minimal. Insider sale disclosures rarely change sector fundamentals for diagnostics/oncology testing names.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale is under a pre-arranged 10b5-1 plan, so it may reflect liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Natera, Inc.

    Company whose executive chairman reported an open-market insider sale under a 10b5-1 plan.

  • insider
    Matthew Rabinowitz

    Executive Chairman and reporting person who sold 1,718 shares at $260.4908 on 2026-07-27.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 14
$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

fool.com6 min
AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min